Residency · Residency · General Surgery
Gallbladder Cancer and Cholangiocarcinoma
Gallbladder Cancer
Epidemiology and Risk Factors
Gallbladder cancer is a relatively rare but aggressive malignancy with an overall 5-year survival of only 5 to 15%. Risk factors include porcelain gallbladder, gallbladder polyps larger than 1 cm, primary sclerosing cholangitis, anomalous pancreaticobiliary duct junction, and chronic Salmonella infection. The most common histology is adenocarcinoma (more than 90% of cases). There is a female predominance, with higher incidence in Native American, Chilean, and Indian populations. The majority of cases (up to 70%) are discovered incidentally at the time of cholecystectomy.
Staging (AJCC 8th Edition)
| T Stage | Depth of Invasion | Management |
|---|---|---|
| Tis | Carcinoma in situ | Cholecystectomy |
| T1a | Lamina propria | Simple cholecystectomy (curative) |
| T1b | Muscular layer | Radical re-resection (controversial) |
| T2a | Perimuscular connective tissue (peritoneal side) | Radical cholecystectomy |
| T2b | Perimuscular connective tissue (hepatic side) | Radical cholecystectomy |
| T3 | Serosa perforation and/or liver/one adjacent organ | Extended resection |
| T4 | Portal vein/hepatic artery or ≥2 extrahepatic organs | Extended resection if feasible |
The T staging system defines the depth of invasion. Tis is carcinoma in situ. T1a invades the lamina propria, while T1b invades the muscular layer. T2a invades the perimuscular connective tissue on the peritoneal side, and T2b invades the perimuscular connective tissue on the hepatic side. T3 involves perforation of the serosa and/or direct invasion of the liver and/or one adjacent organ. T4 indicates invasion of the portal vein or hepatic artery or two or more extrahepatic organs.
Incidental Gallbladder Cancer
When gallbladder cancer is found on pathology after routine cholecystectomy, management depends on the T stage. For T1a disease, simple cholecystectomy is curative with greater than 95% 5-year survival, and no re-resection is needed. For T1b disease, the approach is controversial, but most guidelines recommend radical re-resection given 15 to 20% node positivity. For T2 and above, radical re-resection is required. A radical cholecystectomy consists of liver resection (segments IVb and V with a minimum 2 cm margin) plus regional lymphadenectomy (hepatoduodenal ligament, portocaval, and retroduodenal nodes). Port-site excision was previously recommended but is no longer routinely performed as it has no proven survival benefit. If the gallbladder was perforated during the initial cholecystectomy, there is concern for upstaging and increased risk of peritoneal dissemination.
Preoperative Workup for Re-Resection
The workup includes CT of the chest, abdomen, and pelvis with contrast, liver MRI, and PET-CT to evaluate for distant metastatic disease. Diagnostic laparoscopy is particularly valuable, as it upstages approximately 25% of patients by identifying peritoneal carcinomatosis. Review of the original pathology and operative note (particularly the cystic duct margin status) is essential.
<image>Axial CT scan showing a gallbladder mass with invasion into the liver parenchyma and regional lymphadenopathy consistent with gallbladder carcinoma</image>
Surgical Resection
If the cystic duct margin is positive, bile duct resection with Roux-en-Y hepaticojejunostomy is required. Extended hepatectomy may be needed for T3 or T4 disease involving major vascular structures. An adequate lymph node harvest of a minimum of 6 nodes is recommended. Adjuvant therapy consists of capecitabine (supported by the BILCAP trial showing an overall survival benefit) or gemcitabine plus cisplatin.
Gallbladder Polyps
Gallbladder polyps larger than 1 cm warrant cholecystectomy because 15 to 20% harbor malignancy. Polyps measuring 6 to 9 mm should be monitored with ultrasound surveillance, with cholecystectomy if they are growing. Polyps smaller than 6 mm require surveillance only in patients with risk factors; otherwise, reassurance is appropriate.
Cholangiocarcinoma
Classification by Anatomic Location
Cholangiocarcinoma is classified by anatomic location. Intrahepatic cholangiocarcinoma (iCCA) accounts for 10 to 20% of cases and arises within the liver parenchyma. Perihilar cholangiocarcinoma (pCCA), also known as a Klatskin tumor, is the most common subtype at 50 to 60% and arises at or near the hepatic duct confluence. Distal cholangiocarcinoma (dCCA) accounts for 20 to 30% and occurs in the common bile duct.
Risk Factors
Primary sclerosing cholangitis (PSC) is the strongest risk factor, conferring a 10 to 15% lifetime risk. Other risk factors include hepatolithiasis, choledochal cysts, Caroli disease, liver flukes (Opisthorchis viverrini and Clonorchis sinensis, which are endemic in Southeast Asia), chronic hepatitis B or C, cirrhosis, and NAFLD (particularly for intrahepatic CCA). Thorotrast exposure is a historical risk factor.
Perihilar Cholangiocarcinoma (Klatskin Tumor)
Bismuth-Corlette Classification
| Bismuth-Corlette Type | Ductal Involvement | Surgical Approach |
|---|---|---|
| I | Below confluence | Bile duct resection ± limited hepatectomy |
| II | Reaches confluence, no R/L duct involvement | Bile duct resection ± limited hepatectomy |
| IIIa | Extends into right hepatic duct | Right hepatectomy + caudate + bile duct resection |
| IIIb | Extends into left hepatic duct | Left hepatectomy + caudate + bile duct resection |
| IV | Both right and left hepatic ducts | Generally unresectable; consider transplant |
The Bismuth-Corlette classification defines the extent of ductal involvement. Type I is below the confluence of the right and left hepatic ducts. Type II reaches the confluence but does not involve the right or left duct. Type IIIa extends into the right hepatic duct. Type IIIb extends into the left hepatic duct. Type IV involves both right and left hepatic ducts (multicentric or bilateral).
Workup
The workup includes high-quality cross-sectional imaging (CT with arterial and venous phases, liver MRI with MRCP) to assess the extent of biliary involvement, vascular encasement (portal vein, hepatic artery), hepatic lobar atrophy, and lymphadenopathy. CA 19-9 is elevated in more than 70% of cases but is non-specific, as it may also be elevated in cholangitis and biliary obstruction. Tissue diagnosis is often difficult -- brush cytology at ERCP has a low sensitivity of 30 to 50%, though FISH analysis improves yield. PET-CT is used for nodal and distant staging.
Biliary Drainage
Preoperative biliary drainage of the future liver remnant is indicated if the patient is jaundiced and a major hepatectomy is planned. Percutaneous transhepatic biliary drainage (PTBD) is preferred over ERCP for perihilar tumors because it carries a lower risk of infecting the FLR. Only the FLR should be drained -- contamination of the liver to be resected increases postoperative sepsis risk.
Surgical Management
The standard resection for perihilar cholangiocarcinoma is en bloc hepatic resection with caudate lobectomy plus bile duct resection plus regional lymphadenectomy plus Roux-en-Y hepaticojejunostomy. Caudate resection is essential because the caudate ducts drain directly into the confluence. For Type I and II tumors, bile duct resection with or without limited hepatectomy may suffice. Type IIIa requires right hepatectomy plus caudate resection plus bile duct resection. Type IIIb requires left hepatectomy plus caudate resection plus bile duct resection. Type IV is generally unresectable, though liver transplant may be considered in selected cases. Portal vein embolization is indicated if the FLR is less than 30 to 40% after the planned hepatectomy. Vascular resection and reconstruction (of the portal vein) may be needed and is acceptable.
Liver Transplantation for Perihilar CCA
The Mayo Clinic protocol involves neoadjuvant chemoradiation followed by liver transplantation under strict selection criteria: unresectable disease or disease arising in PSC, tumor size less than 3 cm, no extrahepatic disease, and negative staging laparotomy and transperitoneal biopsy. This achieves 5-year recurrence-free survival of 65 to 70% in highly selected patients. The approach is not widely available and requires a specialized center and protocol.
<image>Bismuth-Corlette classification diagram of perihilar cholangiocarcinoma showing Types I through IV with their relationship to the hepatic duct confluence</image>
Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma presents as a liver mass and is often diagnosed on imaging. The differential includes HCC and metastatic disease. Surgical treatment consists of anatomic hepatectomy with negative margins plus lymphadenectomy (portal and celiac nodes). Lymph node status is the strongest prognostic factor. The periductal infiltrating type carries a worse prognosis than the mass-forming type. Adjuvant therapy is capecitabine (extrapolated from BILCAP) or gemcitabine-based regimens.
Distal Cholangiocarcinoma
Distal cholangiocarcinoma presents with painless obstructive jaundice. Treatment is pancreaticoduodenectomy (Whipple procedure). It has a better prognosis than perihilar CCA, with 5-year survival of 20 to 40% after R0 resection. Lymphadenectomy of the pancreaticoduodenal, periportal, and celiac nodes is performed.
<image>MRI/MRCP showing perihilar cholangiocarcinoma with biliary obstruction and dilation of intrahepatic bile ducts proximal to the tumor at the hepatic duct confluence</image>
Systemic Therapy
Advanced/Unresectable Disease
First-line treatment is gemcitabine plus cisplatin (the ABC-02 trial showed overall survival of 11.7 versus 8.1 months). Second-line therapy is FOLFOX (ABC-06 trial). Targeted therapy based on molecular profiling includes ivosidenib for IDH1 mutations, pemigatinib or futibatinib for FGFR2 fusions, pembrolizumab for MSI-H/dMMR tumors, and trastuzumab deruxtecan for HER2 amplification (emerging data).
Adjuvant Therapy
The BILCAP trial demonstrated that capecitabine for 6 months improved overall survival in the per-protocol analysis for resected biliary tract cancers. This has become the standard of care for adjuvant therapy in resected cholangiocarcinoma and gallbladder cancer.
Clinical Pearls
The gallbladder should always be submitted for pathologic examination after cholecystectomy, as incidental gallbladder cancer is found in 0.2 to 0.7% of specimens. For incidental T1a gallbladder cancer, simple cholecystectomy is sufficient, while T1b and above requires referral for radical re-resection after staging. Percutaneous biopsy of suspected perihilar cholangiocarcinoma should not be performed because the risk of needle-track seeding may preclude transplant candidacy. CA 19-9 can be falsely elevated with biliary obstruction and should be rechecked after drainage. Caudate lobectomy is a critical component of resection for perihilar CCA because caudate ducts drain directly into the confluence. PSC patients with a new dominant stricture or rising CA 19-9 should raise concern for cholangiocarcinoma and undergo ERCP with brushings and FISH.
References
- Aloia TA, et al. Gallbladder cancer: Expert consensus statement. HPB. 2015;17(8):681-690.
- Jarnagin WR, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507-517.
- Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02). N Engl J Med. 2010;362(14):1273-1281.
- Primrose JN, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP). Lancet Oncol. 2019;20(5):663-673.
- Darwish Murad S, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma. Gastroenterology. 2012;143(1):88-98.
